Startup Company Profile
Antigen Discovery, Inc. (formerly ImmPort therapeutics)
|
One Technology Suite E309 |
Employees: 12 |
|||
|
Faculty Inventors:
|
||||
Antigen Discovery's revolutionary technology enables fast, comprehensive and high-throughput analysis of immune responses to infectious disease antigens. It is ideal for vaccine and diagnostics development or clinical analysis. A pre-printed array for simultaneous serological detection of multiple infectious agents is available in early 2007 (learn more about "PathogenChip"). The technology is also available as a custom whole proteome synthesis, micro-array fabrication and analysis service.
The primary competitive benefits are:
- Much faster results: starting from gene sequences and genomic DNA, we express, array and screen all antigens in the proteome within weeks.
- Much higher success rate : high efficiency cell free expression system with tolerance for toxic genes (> 95% of viral and bacterial genes have been successfully expressed).
- Much better sensitivity and dynamic range: suitable for serum screening assays with minute sample volumes and over a wide range of sample dilution.
- Reliable to use: built in controls (e.g. built in QC elements) to help eliminate false negatives and false positives.
- Much more economic: proprietary technology dramatically reduces the cost and time over conventional approaches. Analysis can be done using standard fluorescence or colorimetric assays.
- Highly Flexible: please contact us to inquire about pre-printed and custom arrays, e.g. entire proteomes or selected antigens/domains. Services include analyses of customer samples and array design.
